Gimme Five

  • by: |
  • 06/28/2012

CDER’s Office of Prescription Drug Promotion (OPDP) has decided to issue five separate guidance documents that will address “social media” issues that have arisen in advertising and promotion areas. “We decided not to issue just one guidance because it would be burdensome and changing all the time,” OPDP director Tom Abrams told a Drug Industry Association conference in Philadelphia 6/25. ”Instead, guidance will be developed on policy-specific issues and not on any specific technology platform. We don't know what the platforms will be in two years. We know Facebook, Twitter, and Youtube are very popular now, but we don't know how they will evolve or what new platforms will be available next year...So to try to have a guidance based on one platform, such as Facebook, would be a mistake and quickly outdated. And we are developing guidance applicable to whatever platform companies my use for prescription drug promotion.”

A guidance under development is on Fulfilling Regulatory Requirements When Using Tools Associated with Space Limitations, which will address how to include risk information when there is a character limitation such as Twitter, Abrams said.

A guidance on Fulfilling Post-marketing Submission Reporting Requirements is under development to address how to submit promotional material at the time of initial use when engaging patients and others in chat rooms, Abrams told the conference. Other guidances will touch on the appropriate use of hyperlinks, and the best practices for correcting misinformation on third-party Web sites.

Without providing any specific timeline for issuance, Abrams said OPDP has assigned substantial resources to the guidance development and other areas, like the Office of Chief Counsel, are also helping with their drafts.

CMPI

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog